CX-5461
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CX-5461, covering 2025-08-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer [Phase 1]